Physician profile
Jeffrey P Schaffer
NPI 1700854270
$6,216.23
in general payments reported to CMS, 2019-2025
26 companies · $827 in 2025
The $827 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $808 · 2020: $920 · 2021: $1,241 · 2022: $965 · 2023: $842 · 2024: $613 · 2025: $827.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,282.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,197.64 | 2019-2025 | Farxiga, Lokelma, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $881.19 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $718.65 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $551.45 | 2020-2025 | Verquvo, Steglatro, Capvaxive |
| Pfizer INC. | $487.93 | 2019-2025 | |
| Glaxosmithkline, LLC. | $486.96 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $478.21 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $269.93 | 2019-2025 | |
| Esperion Therapeutics, INC. | $230.68 | 2020-2025 | Nexletol |
| Amarin Pharma, INC. | $208.02 | 2019-2021 | |
| Vifor Pharma, INC. | $200.00 | 2021 | |
| Amgen INC. | $66.51 | 2019-2024 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $66.23 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $59.99 | 2023 | Austedo Xr, Austedo |
| Abbott Laboratories | $46.49 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bardy Diagnostics, INC. | $41.02 | 2022 | |
| Abbvie INC. | $32.60 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $28.33 | 2019 | |
| Neurocrine Biosciences, INC. | $25.88 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $25.27 | 2025 | |
| Sanofi-Aventis U.S. LLC | $22.42 | 2020 | |
| Eisai INC. | $19.55 | 2021 | |
| Allergan, INC. | $18.43 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $18.02 | 2021 | |
| Lundbeck LLC | $17.50 | 2019 | |
| Boston Scientific Corporation | $17.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Schaffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.